Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Aug 3;89(12):1332–1340. doi: 10.1136/jnnp-2018-318107

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

PMC Copyright notice

Changes in UPDRS-III scores and L-Dopa equivalent dose of dopaminergic replacement therapy (LDED). (A) In the donepezil group, UPDRS-III scores were transiently elevated by starting and dose escalation (3–5 mg/day) of donepezil, but then returned to baseline and remained stable. In the placebo group, the scores were stable. There were no statistically significant differences in UDPRS-III changes between donepezil and placebo groups. (B) Dopaminergic drug doses were elevated gradually in both donepezil and placebo groups and were slightly larger with donepezil than with placebo. The difference was not statistically significant. Data represent the mean with 95% CIs.